Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338056
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenue | 350 | 677 | 3,350 | 8,355 |
| Operating expenses: | ||||
| Research and development expenses | $76,483 | $63,897 | $147,046 | $137,706 |
| General and administrative expenses | 14,691 | 13,627 | 25,718 | 32,366 |
| Total operating expenses | 91,174 | 77,524 | 172,764 | 170,072 |
| Loss from operations | (90,824) | (76,847) | (169,414) | (161,717) |
| Other income: | ||||
| Interest income | 7,115 | 7,105 | 12,467 | 14,918 |
Item 1. Financial Statements.
FAQ
- What is Relay Therapeutics, Inc.'s G&A?
- Relay Therapeutics, Inc. (RLAY) reported G&A of $14.69M in Q2 2026.
- How has Relay Therapeutics, Inc.'s G&A changed year-over-year?
- Relay Therapeutics, Inc.'s G&A increased by 7.8% year-over-year, from $13.63M to $14.69M.
- What is the long-term trend for Relay Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s G&A has grown at a -0.3% compound annual growth rate (CAGR), from $57.39M to $56.71M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Relay Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude